NCT03742713: CINOVA

Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer

Completed Phase 2 Last updated 28 December 2020

What this trial tests

Phase 2 trial testing CPC634 (CriPec® docetaxel) in Cancer in 25 participants. Completed in 1 December 2020.

Timeline

1 October 2018

Primary endpoint
1 December 2020

1 December 2020

Quick facts

Lead sponsor	Cristal Therapeutics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 October 2018
Primary completion	1 December 2020
Estimated completion	1 December 2020
Sites	8 locations across Belgium, United Kingdom, Netherlands

Drugs / interventions tested

• CPC634 (CriPec® docetaxel) — full drug profile →

Conditions studied

• Cancer — all drugs for Cancer →
• Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Cristal Therapeutics — full company profile →

Who can join

18 and older, female only, with Cancer or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether CPC634 (CriPec® docetaxel) is effective in the treatment of patients with advanced epithelial ovarian cancer who are resistant to prior platinum-based chemotherapy

.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Nanoparticles in the clinic: An update.
   Anselmo AC, Mitragotri S. · · 2019 · cited 976× · PMID 31572799 · DOI 10.1002/btm2.10143
2. Targeted drug delivery strategies for precision medicines.
   Manzari MT, Shamay Y, Kiguchi H, Rosen N, et al · · 2021 · cited 619× · PMID 34950512 · DOI 10.1038/s41578-020-00269-6
3. Polymeric Nanoparticles for Drug Delivery.
   Beach MA, Nayanathara U, Gao Y, Zhang C, et al · · 2024 · cited 476× · PMID 38626459 · DOI 10.1021/acs.chemrev.3c00705
4. Smart nanoparticles for cancer therapy.
   Sun L, Liu H, Ye Y, Lei Y, et al · · 2023 · cited 474× · PMID 37919282 · DOI 10.1038/s41392-023-01642-x
5. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.
   Hwang D, Ramsey JD, Kabanov AV. · · 2020 · cited 376× · PMID 32980449 · DOI 10.1016/j.addr.2020.09.009
6. Current advance of nanotechnology in diagnosis and treatment for malignant tumors.
   Wang B, Hu S, Teng Y, Chen J, et al · · 2024 · cited 251× · PMID 39128942 · DOI 10.1038/s41392-024-01889-y
7. Nanoparticles in the clinic: An update post COVID-19 vaccines.
   Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246
8. Nanoparticles in Clinical Translation for Cancer Therapy.
   Mundekkad D, Cho WC. · · 2022 · cited 146× · PMID 35163607 · DOI 10.3390/ijms23031685